Cargando…

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia

Nilotinib, a second-generation tyrosine kinase inhibitor, is used for treatment of chronic myeloid leukemia (CML); it has been widely used especially for imatinib-resistant CML. Despite being a novel drug in this therapeutic class, it has the potential to be harmful. We present the case of an elderl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Vihang, Pattisapu, Anil, Attia, Karim, Weiss, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471777/ https://www.ncbi.nlm.nih.gov/pubmed/28626381 http://dx.doi.org/10.1159/000468510

Ejemplares similares

Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response
por: Wang, Shifang, et al.
Publicado: (2020)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
por: Maruta, Shunsuke, et al.
Publicado: (2021)

A Case of Acute Myeloid Leukemia-Associated Necrotizing Sweet Syndrome
por: Strong, Jennifer, et al.
Publicado: (2022)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
por: Al-Dubai, Husam N., et al.
Publicado: (2020)

Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia
por: Chan, Justine, et al.
Publicado: (2019)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

Nilotinib-Induced Diabetes Mellitus in a Young Female with Chronic Myeloid Leukemia
por: Ismail, Abdel-Latif S, et al.
Publicado: (2020)

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report
por: Caocci, Giovanni, et al.
Publicado: (2014)

Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
por: Sanford, David, et al.
Publicado: (2014)

OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia
por: Kiriyama, Hiroyuki, et al.
Publicado: (2019)

Severe Hypertriglyceridemia-Induced Acute Pancreatitis
por: Molnár, Gyula, et al.
Publicado: (2021)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
por: Piccaluga, Pier Paolo, et al.
Publicado: (2012)

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
por: Drube, Julia, et al.
Publicado: (2018)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

Nilotinib-Induced Elephantine Psoriasis In a Patient With Chronic Myeloid Leukemia: A Rare Case Report and Literature Review
por: Sadatmadani, Seyedeh Fatemeh, et al.
Publicado: (2022)

Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
por: Onaka, Takashi, et al.
Publicado: (2017)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
por: Okamoto, Yuji, et al.
Publicado: (2022)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase
por: Takatsuka, Ibuki, et al.
Publicado: (2022)

Intravenous Immunoglobulin Therapy-Induced Erythema Multiforme in a Patient with Chronic Lymphocytic Leukemia
por: Konovalova, Angelina, et al.
Publicado: (2023)

Symptomatic Acute Pancreatitis Induced by Nilotinib: A Report of Two Cases
por: Yamada, Toshiki, et al.
Publicado: (2016)

Successful Peripheral Blood Stem Cells Collection in Imatinib Pretreated and Nilotinib-Treated Chronic Myeloid Leukemia Patient
por: Vokurka, Samuel, et al.
Publicado: (2010)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature
por: Sekiguchi, Yasunobu, et al.
Publicado: (2015)

Eosinophilic Pancreatitis: A Rare Cause of Recurrent Acute Pancreatitis
por: Reppucci, Jennifer, et al.
Publicado: (2017)

Hypothermia-Related Acute Pancreatitis
por: Lin, Kyawzaw, et al.
Publicado: (2018)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
por: Cengiz Seval, Güldane, et al.
Publicado: (2017)

Pancreatitis Induced by Cocaine
por: Chapela, Sebastián Pablo, et al.
Publicado: (2017)

Acute Pancreatitis after Biliary and Pancreatic Stent Removal with a Forward-Viewing Endoscope
por: Okamoto, Takeshi, et al.
Publicado: (2021)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

Pancreatic Pseudocyst Ruptured due to Acute Intracystic Hemorrhage
por: Okamura, Kunishige, et al.
Publicado: (2017)

Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?
por: Capuozzo, Maurizio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ktruh3l9dmrnjm5iq3epo4v3mr